Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study

Objective: To investigate the influence of COVID-19 vaccination on disease activity in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients under targeted therapies. Patients and methods: 1765 vaccinated patients COVID-19, 1178 (66.7%) with RA and 587 (33.3%) with PsA from the COVID-19 r...

Full description

Bibliographic Details
Authors: Álvaro-Gracia, José M, Sanchez-Piedra, Carlos, Culqui, Dante, Rosello, Rosa, Garcia-Dorta, Alicia, Campos, Cristina, Manrique-Arija, Sara, Ruiz-Montesinos, Dolores, Ros-Vilamajo, Inmaculada, Rodríguez-Lozano, Carlos, Freire-González, Mercedes, Caliz, Rafael, Bohorquez, Cristina, Mateo Soria, Lourdes, Busquets, Noemí, Castrejón, Isabel, Sánchez-Alonso, Fernando, González-Dávila, Enrique, Díaz-González, Federico
Format: article
Publication Date:2023
Country:España
Institution:Instituto de Salud Carlos III (ISCIII)
Repository:Repisalud
Language:English
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/16474
Online Access:http://hdl.handle.net/20.500.12105/16474
Access Level:Open access
Keyword:Arthritis, Psoriatic
COVID-19
Arthritis, Rheumatoid
Humans
Interleukin-6
Interleukin-12
id ES_5d8593a5440ca960b681b237f2f4b4c8
oai_identifier_str oai:repisalud.isciii.es:20.500.12105/16474
network_acronym_str ES
network_name_str España
repository_id_str
spelling Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER studyÁlvaro-Gracia, José MSanchez-Piedra, CarlosCulqui, DanteRosello, RosaGarcia-Dorta, AliciaCampos, CristinaManrique-Arija, SaraRuiz-Montesinos, DoloresRos-Vilamajo, InmaculadaRodríguez-Lozano, CarlosFreire-González, MercedesCaliz, RafaelBohorquez, CristinaMateo Soria, LourdesBusquets, NoemíCastrejón, IsabelSánchez-Alonso, FernandoGonzález-Dávila, EnriqueDíaz-González, FedericoArthritis, PsoriaticCOVID-19Arthritis, RheumatoidHumansInterleukin-6Interleukin-12Objective: To investigate the influence of COVID-19 vaccination on disease activity in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients under targeted therapies. Patients and methods: 1765 vaccinated patients COVID-19, 1178 (66.7%) with RA and 587 (33.3%) with PsA from the COVID-19 registry in patients with rheumatic diseases (COVIDSER) project, were included. Demographics, disease characteristics, Disease Activity Score in 28 joints (DAS28) and targeted treatments were collected. DAS28-based flare rates and categorised disease activity distribution prevaccination and post vaccination were analysed by log-linear regression and contingency analyses, respectively. The influence of vaccination on DAS28 variation as a continuous measure was evaluated using a random coefficient model. Results: The distribution of categorised disease activity and flare rates was not significantly modified by vaccination. Log-linear regression showed no significant changes in the rate of flares in the 6-month period after vaccination compared with the same period prior to vaccination in neither patients with RA nor patients with PsA. When DAS28 variations were analysed using random coefficient models, no significant variations in disease activity were detected after vaccination for both groups of patients. However, patients with RA treated with Janus kinase inhibitors (JAK-i) (1) and interleukin-6 inhibitor (IL-6-i) experienced a worsening of disease activity (1.436±0.531, p=0.007, and 1.201±0.550, p=0.029, respectively) in comparison with those treated with tumour necrosis factor inhibitor (TNF-i). Similarly, patients with PsA treated with interleukin-12/23 inhibitor (IL-12/23-i) showed a worsening of disease activity (4.476±1.906, p=0.019) compared with those treated with TNF-i. Conclusion: COVID-19 vaccination was not associated with increased rate of flares in patients with RA and PsA. However, a potential increase in disease activity in patients with RA treated with JAK-i and IL-6-i and in patients with PsA treated with IL-12/23-i warrants further investigation.BMJ Publishing GroupBristol-Myers SquibbRocheGalapagos Biopharma Spain20232023-09-1520232023-03-0120232023-03-01research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/20.500.12105/16474reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Atribución 4.0 Internacionalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repisalud.isciii.es:20.500.12105/164742026-06-12T12:43:37Z
dc.title.none.fl_str_mv Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study
title Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study
spellingShingle Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study
Álvaro-Gracia, José M
Arthritis, Psoriatic
COVID-19
Arthritis, Rheumatoid
Humans
Interleukin-6
Interleukin-12
title_short Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study
title_full Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study
title_fullStr Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study
title_full_unstemmed Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study
title_sort Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study
dc.creator.none.fl_str_mv Álvaro-Gracia, José M
Sanchez-Piedra, Carlos
Culqui, Dante
Rosello, Rosa
Garcia-Dorta, Alicia
Campos, Cristina
Manrique-Arija, Sara
Ruiz-Montesinos, Dolores
Ros-Vilamajo, Inmaculada
Rodríguez-Lozano, Carlos
Freire-González, Mercedes
Caliz, Rafael
Bohorquez, Cristina
Mateo Soria, Lourdes
Busquets, Noemí
Castrejón, Isabel
Sánchez-Alonso, Fernando
González-Dávila, Enrique
Díaz-González, Federico
author Álvaro-Gracia, José M
author_facet Álvaro-Gracia, José M
Sanchez-Piedra, Carlos
Culqui, Dante
Rosello, Rosa
Garcia-Dorta, Alicia
Campos, Cristina
Manrique-Arija, Sara
Ruiz-Montesinos, Dolores
Ros-Vilamajo, Inmaculada
Rodríguez-Lozano, Carlos
Freire-González, Mercedes
Caliz, Rafael
Bohorquez, Cristina
Mateo Soria, Lourdes
Busquets, Noemí
Castrejón, Isabel
Sánchez-Alonso, Fernando
González-Dávila, Enrique
Díaz-González, Federico
author_role author
author2 Sanchez-Piedra, Carlos
Culqui, Dante
Rosello, Rosa
Garcia-Dorta, Alicia
Campos, Cristina
Manrique-Arija, Sara
Ruiz-Montesinos, Dolores
Ros-Vilamajo, Inmaculada
Rodríguez-Lozano, Carlos
Freire-González, Mercedes
Caliz, Rafael
Bohorquez, Cristina
Mateo Soria, Lourdes
Busquets, Noemí
Castrejón, Isabel
Sánchez-Alonso, Fernando
González-Dávila, Enrique
Díaz-González, Federico
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Bristol-Myers Squibb
Roche
Galapagos Biopharma Spain
dc.subject.none.fl_str_mv Arthritis, Psoriatic
COVID-19
Arthritis, Rheumatoid
Humans
Interleukin-6
Interleukin-12
topic Arthritis, Psoriatic
COVID-19
Arthritis, Rheumatoid
Humans
Interleukin-6
Interleukin-12
description Objective: To investigate the influence of COVID-19 vaccination on disease activity in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients under targeted therapies. Patients and methods: 1765 vaccinated patients COVID-19, 1178 (66.7%) with RA and 587 (33.3%) with PsA from the COVID-19 registry in patients with rheumatic diseases (COVIDSER) project, were included. Demographics, disease characteristics, Disease Activity Score in 28 joints (DAS28) and targeted treatments were collected. DAS28-based flare rates and categorised disease activity distribution prevaccination and post vaccination were analysed by log-linear regression and contingency analyses, respectively. The influence of vaccination on DAS28 variation as a continuous measure was evaluated using a random coefficient model. Results: The distribution of categorised disease activity and flare rates was not significantly modified by vaccination. Log-linear regression showed no significant changes in the rate of flares in the 6-month period after vaccination compared with the same period prior to vaccination in neither patients with RA nor patients with PsA. When DAS28 variations were analysed using random coefficient models, no significant variations in disease activity were detected after vaccination for both groups of patients. However, patients with RA treated with Janus kinase inhibitors (JAK-i) (1) and interleukin-6 inhibitor (IL-6-i) experienced a worsening of disease activity (1.436±0.531, p=0.007, and 1.201±0.550, p=0.029, respectively) in comparison with those treated with tumour necrosis factor inhibitor (TNF-i). Similarly, patients with PsA treated with interleukin-12/23 inhibitor (IL-12/23-i) showed a worsening of disease activity (4.476±1.906, p=0.019) compared with those treated with TNF-i. Conclusion: COVID-19 vaccination was not associated with increased rate of flares in patients with RA and PsA. However, a potential increase in disease activity in patients with RA treated with JAK-i and IL-6-i and in patients with PsA treated with IL-12/23-i warrants further investigation.
publishDate 2023
dc.date.none.fl_str_mv 2023
2023-09-15
2023
2023-03-01
2023
2023-03-01
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.12105/16474
url http://hdl.handle.net/20.500.12105/16474
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Atribución 4.0 Internacional
http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Atribución 4.0 Internacional
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv BMJ Publishing Group
publisher.none.fl_str_mv BMJ Publishing Group
dc.source.none.fl_str_mv reponame:Repisalud
instname:Instituto de Salud Carlos III (ISCIII)
instname_str Instituto de Salud Carlos III (ISCIII)
reponame_str Repisalud
collection Repisalud
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869409022684168192
score 15,811543

Similar Items